A Phase 1 study of S-337395

A Phase 1 study of S-337395 in healthy adult participants

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031230033

Enrollment

Registered

2023-04-17

Start date

2023-04-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

RS virus infection

Interventions

S-337395 or placebo by oral administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Those who aged >=18 to ==18.5 (kg/m2) to =<30.0 (kg/m2).

Exclusion criteria

Exclusion criteria: Considered by the investigator or subinvestigator (suitably qualified) to be ineligible for the study due to a history of or current condition of significant metabolic or endocrine, hepatic, renal, hematological, cardiovascular, gastrointestinal or neurological disorders that are considered by the investigator to constitute a safety risk upon the study drug administration or to interfere with the interpretation of data.

Design outcomes

Primary

Measure	Time frame
Adverse events, physical examination, laboratory tests (hematology, blood chemistry, and urinalysis), vital signs (systolic and diastolic blood pressure, pulse rate, respiratory rate, and temperature), 12 lead ECG, and Holter ECG	—

Contacts

Public ContactCorporate Communications Department

Shionogi & Co., Ltd.

shionogiclintrials-admin@shionogi.co.jp+81-6-6209-7885

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026